end-stage metastatic gastrointestinal or breast cancer.
Conditions
Interventions
Intervention group: the selected patients go through PET/CT (68Ga-FAPI radiopharmaceutical about 6 mCi dose) or SPECT/CT (99mTc-FAPI radiopharmaceutical about 20 mCi dose) scan at first. The therapeut
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: the patient should be able to understand and sign off the informed consent. The patient should be able to understand and follow the treatment protocol. Patients should be older than 18. The patients life expectancy should be over 6 months. patients should show no response to the standard treatment. The 68Ga-FAPI PET scan or 99mTc-FAPI SPECT scan should show 3 times more uptake of radiopharmaceutical in tumor to liver of the patients. the patient with progressive disease should be included.
Exclusion criteria
Exclusion criteria: The patients who have received therapeutic radiopharmaceuticals like, 223Ra, 188Re, 186Re, 153Sm during last 6 months. The patients are under systemic therapies like chemotherapy, immunotherapy, or biological treatment for cancer. The patients who have been under any research treatment during 28 days before entrance in this study. The patients who have shown any known allergy to the therapeutic radiopharmaceuticals. The patients who have congestive heart failure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of pain feeling on the bone. Timepoint: Just before treatment and every 4 weeks after treatment. Method of measurement: Using Visual Analogue Scale questionnaire.;Performance Status (quality of life). Timepoint: Before treatment and every 4 weeks after treatment. Method of measurement: Eastern Cooperative Oncology Group (ECOG) Performance Status. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactLeila Hassanzadeh
Iran University of Medical Sciences
Outcome results
None listed